Tumores Germinativos Avançados - Tratamento com PVB
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/3200 |
Resumo: | Thirteen patients with advanced germ-cell tumors were treated with PVB chemotherapy at Hospital de Oncologia - INA MPS - Rio de Janeiro, Brazil, during the last three years. One of these patients was not suitable for evaluation. In eight patients there was complete (66.7%) and in four partial remission (33.3%); in two cases relapses ocurred 12 and is 16 months after chemotherapy Three patients died afterpartial remission, two af ter failure of second choice therapeutic scheme (VP16 + CDDP), and one for discontinuing second choice scheme. Only one patient underwent two chemotherapy cicles. Mean follow-up was 21 months. The scheme was considered to be effectual and well tolerated. Remission indexes must be re-evaluated after longer periods of time. |
id |
INCA-1_311a7683cf2e27fb3eb1c6c93584e9f8 |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/3200 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
Tumores Germinativos Avançados - Tratamento com PVBTumores GerminativosQuimioterapiaGerm-Cell TumorsChemotherapyThirteen patients with advanced germ-cell tumors were treated with PVB chemotherapy at Hospital de Oncologia - INA MPS - Rio de Janeiro, Brazil, during the last three years. One of these patients was not suitable for evaluation. In eight patients there was complete (66.7%) and in four partial remission (33.3%); in two cases relapses ocurred 12 and is 16 months after chemotherapy Three patients died afterpartial remission, two af ter failure of second choice therapeutic scheme (VP16 + CDDP), and one for discontinuing second choice scheme. Only one patient underwent two chemotherapy cicles. Mean follow-up was 21 months. The scheme was considered to be effectual and well tolerated. Remission indexes must be re-evaluated after longer periods of time.Treze pacientes portadores de tumores germinativos avançados foram tratados nos últimos três anos no Hospital de Oncologia --- INAMPS com esquema quimioterápico PVB. Destes, um paciente não é avaliável visto ter recebido dois ciclos incompletos e somente um tem apresentação extragonadal, sendo os demais primitivos do testículo. Oito pacientes apresentaram PC (66,7%) e quatro RP (33,3%). Duas recidivas ocorreram 12 e 16 meses após início da quimioterapia. Houve três óbitos, após RP dois por falha ao esquema de 2. linha (VP16 + CDDP) e um por evolução de doença após abandono de tratamento durante esquema de 2.' linha. Somente um paciente recebeu dois ciclos de quimioterapia que corresponde a tumor metacrônico. O período médio de acompanhamento é de 21 meses (oito a 39 meses). A média de ciclos é 3,8. O esquema é eficaz, a tolerabilidade muito boa, porém é necessário maior tempo para confirmarmos o percentual de remissão.INCA2023-08-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/320010.32635/2176-9745.RBC.1987v33n2.3200Revista Brasileira de Cancerologia; Vol. 33 No. 2 (1987): June; 159-166Revista Brasileira de Cancerologia; Vol. 33 Núm. 2 (1987): jun.; 159-166Revista Brasileira de Cancerologia; v. 33 n. 2 (1987): jun.; 159-1662176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/3200/2055https://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessGomes Filho, Firmino de AzevedoViola, Sandra Regina de Souza2023-08-04T18:35:50Zoai:rbc.inca.gov.br:article/3200Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2023-08-04T18:35:50Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
Tumores Germinativos Avançados - Tratamento com PVB |
title |
Tumores Germinativos Avançados - Tratamento com PVB |
spellingShingle |
Tumores Germinativos Avançados - Tratamento com PVB Gomes Filho, Firmino de Azevedo Tumores Germinativos Quimioterapia Germ-Cell Tumors Chemotherapy |
title_short |
Tumores Germinativos Avançados - Tratamento com PVB |
title_full |
Tumores Germinativos Avançados - Tratamento com PVB |
title_fullStr |
Tumores Germinativos Avançados - Tratamento com PVB |
title_full_unstemmed |
Tumores Germinativos Avançados - Tratamento com PVB |
title_sort |
Tumores Germinativos Avançados - Tratamento com PVB |
author |
Gomes Filho, Firmino de Azevedo |
author_facet |
Gomes Filho, Firmino de Azevedo Viola, Sandra Regina de Souza |
author_role |
author |
author2 |
Viola, Sandra Regina de Souza |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Gomes Filho, Firmino de Azevedo Viola, Sandra Regina de Souza |
dc.subject.por.fl_str_mv |
Tumores Germinativos Quimioterapia Germ-Cell Tumors Chemotherapy |
topic |
Tumores Germinativos Quimioterapia Germ-Cell Tumors Chemotherapy |
description |
Thirteen patients with advanced germ-cell tumors were treated with PVB chemotherapy at Hospital de Oncologia - INA MPS - Rio de Janeiro, Brazil, during the last three years. One of these patients was not suitable for evaluation. In eight patients there was complete (66.7%) and in four partial remission (33.3%); in two cases relapses ocurred 12 and is 16 months after chemotherapy Three patients died afterpartial remission, two af ter failure of second choice therapeutic scheme (VP16 + CDDP), and one for discontinuing second choice scheme. Only one patient underwent two chemotherapy cicles. Mean follow-up was 21 months. The scheme was considered to be effectual and well tolerated. Remission indexes must be re-evaluated after longer periods of time. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-08-04 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigos, Avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/3200 10.32635/2176-9745.RBC.1987v33n2.3200 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/3200 |
identifier_str_mv |
10.32635/2176-9745.RBC.1987v33n2.3200 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/3200/2055 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 33 No. 2 (1987): June; 159-166 Revista Brasileira de Cancerologia; Vol. 33 Núm. 2 (1987): jun.; 159-166 Revista Brasileira de Cancerologia; v. 33 n. 2 (1987): jun.; 159-166 2176-9745 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042234449723392 |